Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration  by Kofflard, Marcel J.M et al.
Hypertrophic Cardiomyopathy in a
Large Community-Based Population:
Clinical Outcome and Identification of Risk Factors
for Sudden Cardiac Death and Clinical Deterioration
Marcel J. M. Kofflard, MD,† Folkert J. Ten Cate, MD, FACC,* Chris van der Lee, MD,*
Ron T. van Domburg, MSC*
Rotterdam and Dordrecht, The Netherlands
OBJECTIVES This study evaluates the clinical course and identifies risk factors for sudden cardiac death
(SCD) and clinical deterioration in hypertrophic cardiomyopathy (HCM) in a large
community-based population. Comparison was made with data from six tertiary referral and
six nonreferral institutions.
BACKGROUND Hypertrophic cardiomyopathy is a disease with marked heterogeneity in clinical presentation
and prognosis. Risk factors for SCD are not well defined in patients free of referral bias.
METHODS Between 1970 and 1999, 225 consecutive patients (mean age [SD] 4116 years) were
examined and followed at yearly intervals.
RESULTS Forty-four deaths were recorded of which 27 cases were cardiovascular. Fourteen patients
died suddenly, six were successfully resuscitated, and seven patients died of congestive heart
failure. The annual mortality, annual cardiac mortality, and annual mortality due to sudden
death were 1.3%, 0.8%, and 0.6%, respectively. At least one New York Heart Association
(NYHA) functional class deterioration was reported in 33% of the patients with a significant
(50 mm Hg) left ventricular outflow tract (LVOT) gradient in contrast to 7% without
obstruction. The presence of syncope was related to SCD (p  0.05). Younger age and more
severe functional limitation distinguishes patients from in hospital-based centers from the
ones in community-based centers.
CONCLUSIONS Hypertrophic cardiomyopathy is a benign disease in an unselected population with a low
incidence of cardiac death. Syncope was associated with a higher incidence of SCD and
patients with a significant LVOT obstruction were more susceptible to clinical
deterioration. (J Am Coll Cardiol 2003;41:987–93) © 2003 by the American College of
Cardiology Foundation
Hypertrophic cardiomyopathy (HCM) is a complex cardiac
disease with a heterogeneous genetic, morphologic, and
clinical spectrum (1,2). In recent years, numerous mutations
in different genes, encoding for proteins of the cardiac
sarcomere, have been found to be responsible for this disease
(3–6). Unfortunately, the same mutation will not always
result in identical morphological and clinical features (7,8).
Environmental as well as genetic factors may modify the
phenotypic expression of the mutated gene (3,8,9).
See page 994
The diverse clinical and genetic characteristics make it
difficult to establish general guidelines for the treatment of
symptoms and to predict which patient is prone to sudden
death. Most of our knowledge concerning the natural
history and risk for premature sudden cardiac death (SCD)
has been derived from the studies of hospital-based popu-
lations (10–18). These studies reported an annual mortality
rate of 2% to 4% in adults and 6% in children. However, the
clinical outcome and perception of risk factors in HCM is
profoundly affected by a bias in patient selection (19).
Studies from nonreferral centers suggested a more benign
clinical course and a fairly favorable prognosis with an
annual mortality of 1% (20–26). However, risk factors for
SCD in patients with HCM have not been extensively
studied in these community-based populations. The pur-
pose of the present study was to evaluate the clinical course
and to identify the presence of risk factors for SCD and
clinical deterioration in a population of relatively unselected
patients with HCM. We compare our results with the
results from hospital-based and community-based popula-
tions.
METHODS
Patient selection. Before 1979, only M-mode and two-
dimensional echocardiography (no Doppler) were available
at our institution and the diagnosis of HCM was also made
by the presence of typical clinical, electrocardiographic,
and/or angiographic findings. The diagnosis of HCM was
later based on the echocardiographic finding of a nondilated
hypertrophic left ventricle in the absence of diseases known
to cause ventricular hypertrophy (1,2). Patients who visit our
HCM clinic are relatively unselected and consist of patients
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who are: 1) diagnosed and treated at our center; 2) referred
from the community for establishment of the diagnosis or
advice on management; 3) transferred from outlying hospi-
tals for advanced care; and 4) self-referred family members
of patients.
Follow-up. Between 1970 and 1999, 225 consecutive pa-
tients were examined initially and followed at yearly inter-
vals. The population included 113 patients as reported
earlier (22). The other 112 patients consisted of patients
who were brought to our attention from 1990. At first visit,
clinical characteristics including age at diagnosis of HCM,
family history of HCM or sudden death in a first degree
relative at a young age (40 years) or both, symptoms, New
York Heart Association (NYHA) functional class, and the
drugs prescribed, were recorded. Physical examination and
baseline laboratory studies were performed including elec-
trocardiogram, M-mode and two-dimensional echocardiog-
raphy (as well as Doppler echocardiography after 1985), and
in the majority of patients, 24-h ambulatory Holter moni-
toring. Cardiac catheterization was performed only in pa-
tients with symptoms refractory to medical therapy in whom
surgical treatment was considered. Follow-up information
was obtained within six months from August 1999 at the
outpatient clinic or, if the patient moved out of Rotterdam,
from their private cardiologist. No patient was lost to
follow-up. Cardiac death was defined as death caused by
congestive heart failure or sudden death. All deaths wit-
nessed within 1 h of onset of symptoms or in subjects
known to be in normal functioning 24 h before, were
assumed to be SCDs. Patients who were successfully rean-
imated after cardiac arrest during follow-up were classified
as SCD for the purpose of analysis.
Review of the literature on prognosis in patients with
HCM. To compare our study findings, we reviewed the
literature on prognosis in HCM in both hospital-based and
community-based institutions. A total of nine studies from
six hospital-based centers and six studies from six
community-based centers were found for comparison.
Statistics. Data are expressed as mean value  SD. Cu-
mulative survival estimates and 95% confidence intervals
(CIs) were calculated according to the Kaplan-Meier
method. Among patient subgroups the log-rank test was
used to evaluate differences in survival between subgroups.
The yearly cumulative mortality rate was calculated on the
basis of all available follow-up time. To assess risk factors
for cardiac death and clinical deterioration, univariate and
multivariate analysis was performed using the Cox regres-
sion model.
The chi-squared test was used to compare clinical char-
acteristics from referral and nonreferral centers.
RESULTS
Baseline characteristics. The clinical characteristics of the
225 patients with HCM are listed in Table 1. The majority
of the patients were male (n  130). At first visit, 63
patients (28%) were younger than 30 years and 20 (9%) were
older than 65 years. The mean age (SD) at diagnosis of
HCM was 37  17 years and 41  16 years at presentation
to our institution. A positive family history of HCM was
present in 110 patients (49%), of whom 52 patients (23%)
also reported a sudden death in a first degree relative.
Reported symptoms included angina in 58 patients (26%),
dyspnea in 81 (36%), syncope in 43 (19%), and palpitations
in 43 (19%). At presentation, 100 patients (44%) were
asymptomatic or had trivial symptoms (NYHA functional
class I), 101 patients (45%) had mild symptoms of exertional
angina and/or dyspnea (class II), and 24 patients (11%) were
moderately symptomatic (class III). Initially, patients were
Abbreviations and Acronyms
AF  atrial fibrillation
CI  confidence interval
HCM  hypertrophic cardiomyopathy
LVOT  left ventricular outflow tract
NYHA  New York Heart Association
RR  relative risk
SCD  sudden cardiac death
VT  ventricular tachycardia
Table 1. Baseline Characteristics of 225 Patients With HCM
Number (%)
Patients 225
Male/female 130 (58)/95 (42)
Age (yrs)
30 63 (28)
30–65 142 (63)
65 20 (9)
Mean age (years  SD)
At diagnosis 37  17
At initial visit 41  16
Family history
Positive 110 (49)
Positive  sudden death 52 (23)
Symptoms
Angina pectoris 58 (26)
Dyspnea 81 (36)
Syncope 43 (19)
NYHA functional class
I 100 (44)
II 101 (45)
III 24 (11)
IV 0
Therapy
Beta-blocker 47 (21)
Calcium-antagonist 72 (32)
Beta-blocker and calcium-antagonist 16 (7)
Antiarrhythmics 18 (8)
Other 11 (5)
No medication 61 (27)
Interventricular septal width (mm)
25 30 (13)
25 195 (87)
LVOT gradient (mm Hg)
50 (at rest/provocation) 98 (44)
HCM  hypertrophic cardiomyopathy; LVOT  left ventricular outflow tract;
NYHA  New York Heart Association.
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treated with beta-blocking agents, calcium antagonists, a
combination of beta-blocking agents and calcium antago-
nists, antiarrhythmics, or other cardiac therapy in 47 (21%),
72 (32%), 16 (7%), 18 (8%), and 11 patients (5%), respec-
tively; 61 patients (27%) did not take medication.
On echocardiography, mean interventricular septum
width was 21 4 mm (16 to 40 mm), 30 patients (13%) had
marked left ventricular hypertrophy (interventricular septal
width 25 mm). Left ventricular outflow tract (LVOT)
gradient, at rest or provocation was 50 mm Hg in 98
patients (44%), as determined by Doppler echocardiography
or cardiac catheterization. At the initial visit, 7 patients (3%)
presented with persistent atrial fibrillation (AF). Episodes
of ventricular tachycardia (VT) on 24-h ambulatory Holter
monitoring were registered in 73 of the 149 patients, in
whom recordings were available. At presentation, two pa-
tients had been treated by septal myectomy for LVOT
obstruction.
Clinical outcome. During follow-up, 44 deaths were re-
ported. Twenty-seven deaths (mean age 49  17 years)
could be attributed to cardiovascular causes: 20 (mean age
44  15 years) of these died suddenly, of whom 6 were
successfully resuscitated from a witnessed cardiac arrest and
7 patients (mean age 64 10 years) died of congestive heart
failure (3 patients underwent orthotopic heart transplanta-
tion which is considered a heart failure death). Seventeen
patients (mean age 63  16 years) died of noncardiac
causes: 4 patients died from cerebrovascular accidents and
13 deaths were associated with chronic obstructive lung
disease (3 patients) or malignant diseases (10 patients). The
annual mortality, annual cardiac mortality, and annual
mortality for sudden death was 1.3%, 0.8%, and 0.6%,
respectively. The 5-, 10-, and 15-year cumulative cardiac
survival in our population was 96%, 91%, and 78%, respec-
tively (Fig. 1).
During follow-up, 57 patients underwent septal myec-
tomy, either alone (29 patients) or in combination with
anterior mitral leaflet extension (22 patients) (27), mitral
valve replacement (3 patients) or coronary artery bypass
grafting (3 patients). There was one perioperative death.
After surgical intervention, 47 patients (82%) had improve-
ment of symptoms and 36 patients (63%) were symptom-
free. A total of 10 patients had implantation of a permanent
pacemaker, 3 because of postoperative atrioventricular
block, 3 for sick sinus syndrome, 3 for treatment of the
LVOT obstruction, and 1 patient received an internal
cardiovertor defibrillator after successfully treated ventricu-
lar fibrillation.
Magnitude of left ventricular hypertrophy. Thirty pa-
tients had marked left ventricular hypertrophy at presenta-
tion. Sudden cardiac death was demonstrated in 5 of these
patients (17%) compared with SCD of 15 (13%) in 195
patients without marked hypertrophy. There was no signif-
icant difference in survival for patients with or without
marked left ventricular hypertrophy (p 0.10 and p 0.13,
respectively).
Presence of LVOT obstruction. At the initial evaluation,
98 patients had a LVOT obstruction. Sudden cardiac death
was established in 10 (10%) of 98 patients with obstruction
and in 10 (8%) of 127 patients without obstruction. No
differences in cardiac death or in SCD were found for this
variable. During follow-up (mean 7.5  7 years) deteriora-
tion in at least one functional NYHA class was experienced
by 33 patients (33%) with a LVOT gradient and in the 57
patients who underwent septal myectomy functional dete-
rioration was present in 24 cases (42%) (Fig. 2). In contrast,
only 9 patients (7%) had functional deterioration in the
nonobstructive group of 127 patients (mean follow-up
8.4  6.7 years) (Fig. 3). In the patients who had surgery,
the LVOT gradient did not change over time. However,
“end-stage” disease with deteriorated systolic function was
established in 4 of 41 the not-operated patients with an
LVOT obstruction.
Presence of AF. At the latest visit, 24 patients (mean age
57 11 years) had persistent AF. Persistent AF was present
at initial evaluation in seven patients. Cardiac death and
SCD was established in 4 (16%) and 2 (8%) patients with
persistent AF compared with 23 (11%) and 18 (9%) patients
in sinus rhythm (p  0.49 and p  0.89, respectively). The
presence of AF had no influence on functional deterioration
Figure 1. Kaplan-Meier survival curve of 225 patients with hypertrophic cardiomyopathy (HC) and age-matched controls. Numbers above horizontal axis
refer to numbers of patients at each follow-up period.
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as assessed by the NYHA classification (p  0.10). One
patient with persistent AF died from an ischemic cerebro-
vascular accident.
Presence of VT. Episodes of nonsustained and/or sus-
tained VT on 24-h Holter monitoring were present in 73 of
149 patients in whom one or more recordings were avail-
able. Sudden cardiac death was established in 8 (11%)
patients with VT and 6 (8%) patients without VT on 24-h
Holter monitoring, respectively. There was no significant
difference in cardiac death and SCD in patients with VT on
24-h Holter monitoring (p  0.76 and p  0.78, respec-
tively). Sustained VT was demonstrated in only seven
patients of whom one patient died suddenly.
Multivariate statistical analysis. For the purpose of anal-
ysis, patients were divided according to known or suspected
risk factors for SCD including age, family history of HCM
and/or sudden death, history of syncope, NYHA classifica-
tion, presence of AF, presence of VT on 24-h ambulatory
monitoring, severe left ventricular hypertrophy (25 mm),
and basal outflow tract obstruction (50 mm Hg). By
multivariate analysis, only syncope was an independent
predictor for SCD (relative risk [RR] 4.3, 95% CI 1.8 to
5.9). Furthermore, only an LVOT obstruction was an
independent predictor for functional deterioration during
the follow-up period (RR 1.16, 95% CI 1.08 to 1.25) for
every increase of 10 mm Hg.
Figure 2. Chart showing New York Heart Association (NYHA) functional classification in patients with a left ventricular outflow tract gradient 50 mm
Hg at rest or provocation. The total number of patients with obstructive hypertrophic cardiomyopathy is expressed in bold (n  98). The patients treated
by surgical therapy are expressed in italics (n  57). The first column represents the NYHA functional class of the patients at presentation to our
institution. The second column represents the NYHA functional class of nonoperated patients at their latest visit or the NYHA functional class of patients
treated by surgery just before operation. The third column represents the NYHA functional class of patients treated by surgery at their latest visit.
Figure 3. Chart showing New York Heart Association (NYHA) functional classification in 127 patients without a left ventricular outflow tract gradient.
The first column represents the NYHA functional class of the patients at presentation to our institution. The second column represents the NYHA
functional class of the patients at their latest visit.
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Review of the literature on prognosis in HCM. Nine
reports originated from six referral centers and as a conse-
quence the population in these studies consisted of highly
selected patients (Table 2) (13–21). In the other six reports,
patients came from six nonreferral centers and in these
studies the population was considered nonselected (22–
26,27) (Table 3).
From the available data it can be appreciated that both
annual mortality and annual cardiac mortality is distinctly
higher in referral centers compared with nonreferral centers
(2.4% to 5.9% vs. 0.0% to 2.0% and 1.5% to 3.5% vs. 0.0%
to 1.3%, respectively). In general, the most striking differ-
ences comparing baseline characteristics in hospital-based
and community-based populations were the younger age
and the more severe functional impairment of patients in
referral centers (p  0.001 and p  0.001, respectively).
This might well produce the discrepancy in clinical outcome
in selected patients.
DISCUSSION
The natural history of HCM has been the subject of much
debate among researchers. Observational studies from ter-
tiary referral centers have estimated the annual cardiac death
to be 2% to 4% in adults (10–17) and as high as 6% in
children (13,28). These studies from major referral institu-
tions have been influenced by selection biases (19). Indeed,
in community-based studies patients with HCM have a
more favorable prognosis with 1% annual mortality (20–
26).
Patient-selection biases might lead to misleading conclu-
sions about the significance of risk factors for sudden death.
The present study investigates the role of risk factors for
sudden death in a community-based population of patients
with HCM.
Clinical characteristics in selected and unselected patients.
At the time of the initial visit, mean age was 41 years and
almost 90% of the patients had no or mild cardiac symp-
toms. These findings are comparable with two other large
unselected community-based trials from Cecchi et al. (24)
and Kyriadiks et al. (25) and in contrast with the findings in
tertiary referral centers. This dissimilarity in clinical char-
acteristics has undoubtedly influenced clinical outcome.
However, we can only speculate how younger age and more
severe functional limitation adversely influence prognosis in
hospital-based patients with HCM. A malignant family
history with sudden death at young age or surviving cardiac
arrest and presence and symptoms of HCM in the very
young have been related with adverse outcome and this
might persuade the general cardiologist to refer these
patients to institutions known to have special interest in
HCM (1). Second, the management of patients with HCM
is difficult once symptoms appear. Myocardial ischemia,
abnormal diastolic function, and LVOT obstruction may all
result in symptoms of angina, dyspnea, and syncope (1). The
contribution of each of these mechanisms to the clinicalTa
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picture differs from patient to patient. The general cardiol-
ogist may choose to refer the patient if his/her client
becomes severely symptomatic (1).
Clinical outcome and risk factors for sudden death. The
annual cardiac mortality in our study was 0.8%. Cardiac
death is caused by heart failure or occurs sudden and
unexpected. Many HCM patients who die suddenly are
adolescents or young adults and have previously been
symptom-free (29). The stratification of risk of sudden
death remains unsettled. There seems to be agreement
among investigators that there is a small subgroup of
patients who are particularly at high risk for sudden death.
Patients who have survived cardiac arrest, young patients
with a family history of multiple SCDs, and those with a
malignant gene mutation are especially at substantial risk for
premature death. Young age (11,13,15), syncope (13,30),
family history of HCM and SCD (13,30), functional
cardiovascular status (13), presence of VT (17), positive
exercise test (15,31), presence of a LVOT gradient (18),
marked left ventricular hypertrophy (32), and a abnormal
blood pressure response during exercise (33) are also re-
ported as risk factors of SCD. These data are derived from
hospital-based populations and, therefore, are influenced by
referral bias. The latter phenomenon plays a less important
role in community-based populations with HCM.
However, none of the community-based institutions have
examined the role of risk factors for sudden death. In the
studies by Cecchi et al. (24) and Kyriakis et al. (25) risk
factors for combined sudden and heart failure-related HCM
death were reported. Nevertheless, it is obvious that the
process leading to death in patients with intractable con-
gestive heart failure differs from the mechanism causing
sudden unexpected death in patients with HCM. Heart
failure results from systolic and/or diastolic dysfunction and
SCD results from VT or ventricular fibrillation, either as a
primary event or as a secondary phenomenon triggered by
myocardial ischemia, diastolic dysfunction, LVOT obstruc-
tion, hypotension, or supraventricular tachycardia (1,34). In
our study, risk factors for cardiac death due to congestive
heart failure could not be detected. However, syncope was
associated with SCD at multivariate analysis.
Syncope is a complex entity since several mechanisms
may be responsible for this symptom including supraven-
tricular and ventricular tachyarrhythmias, bradyarrhythmias,
heart block, diastolic dysfunction, myocardial ischemia,
autonomic dysfunction, and LVOT obstruction. Since the
contribution of each of these mechanisms differs from
patient to patient, the treatment of syncope must be
individualized.
At multivariate analysis, only a significant LVOT gradi-
ent was related to deterioration in functional state.
Study limitations. Hypertrophic cardiomyopathy can be
caused by a mutation in one of the genes that encode
proteins of the cardiac sarcomere. At present, there are
obstacles to the translation of HCM genetic research into
practical clinical applications and routine clinical strategy.Ta
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Exercise-induced hypotension is common in young patients
with HCM and this finding has been associated with an
increased risk of sudden death. However, until 1999 we did
not routinely perform exercise tests in patients with HCM.
Conclusions. The results in our study show that prognosis
of HCM in a community-based population is benign and
confirm the current opinion on the natural history in HCM.
The most striking finding was a substantial difference in the
clinical stability of patients with and without LVOT ob-
struction. In nonobstructive patients, a prolonged stable
clinical course is noticed. In obstructive patients, we found
a progressive decline in functional status during follow-up.
Furthermore, syncope was the only risk factor associated
with sudden death.
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